Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug Derived From Sea Squirt Shows Potent Anti-tumour Activity

21.06.2007
The sea-squirt derived drug trabectedin (ecteinascidinin-743) shows anti-tumour activity in more than half of patients with a specific type of cancer, conclude authors of an Article published early Online and in the July edition of The Lancet Oncology.

Dr Federica Grosso, Sarcoma Unit, Instituto Nazionale Tumori, Milan, Italy, and colleagues in sarcoma centres in Boston, London, Lyon and Paris, did a retrospective study of the effect of trabectedin (derived from Ecteinascidia Turbinata) on patients with advanced pre-treated myxoid liposarcomas, a subtype of the liposarcoma group of cancers associated with specific chromosomal mutations.

They found that of 51 patients with myxoid liposarcomas given trabectedin as part of a compassionate-use programme, two saw their tumours disappear completely (complete response) while a further 24 saw the longest diameter of their tumour shrink by at least 30% (partial response), representing an overall response rate of 51%. Previous studies of trabectedin have shown response rates no higher than 20%. Of these 26 patients that responded, 23 had undergone radiological review of their tumours. The authors showed 17 of these 23 had also experienced reduced tumour density prior to the shrinkage or disappearance of their tumour.

In addition, the progression free-survival rate at six months was 88%, whereas previous studies in all soft tissue sarcomas have placed this figure closer to 20%. Median progression-free survival was 14 months.

The authors say: “If the results of this analysis are reproduced in ongoing prospective studies, myxoid sarcoma would represent a uniquely sensitive subgroup to trabectedin treatment in the heterogeneous family of soft-tissue sarcoma.”

Surgical removal is the mainstay of current treatment regimens for soft-tissue sarcoma, but despite this around half of patients develop distant metastases (secondary tumours) and die. Certain drugs, such as anthracyclines and ifosfamide, have shown response rates of 20-40%, but new drugs are needed.

The authors say that a compassionate-use programme of trabectedin treatment remains ongoing. They conclude: “This analysis has resulted in the initiation of two prospective studies to assess the role of trabectedin in the treatment of myxoid liposarcoma in the pre-operative and metastatic settings. Furthermore, the selective mechanism of action for trabectedin in this translocation-related sarcoma is being studied.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com

More articles from Health and Medicine:

nachricht New vaccine production could improve flu shot accuracy
25.07.2017 | Duke University

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Carbon Nanotubes Turn Electrical Current into Light-emitting Quasi-particles

Strong light-matter coupling in these semiconducting tubes may hold the key to electrically pumped lasers

Light-matter quasi-particles can be generated electrically in semiconducting carbon nanotubes. Material scientists and physicists from Heidelberg University...

Im Focus: Flexible proximity sensor creates smart surfaces

Fraunhofer IPA has developed a proximity sensor made from silicone and carbon nanotubes (CNT) which detects objects and determines their position. The materials and printing process used mean that the sensor is extremely flexible, economical and can be used for large surfaces. Industry and research partners can use and further develop this innovation straight away.

At first glance, the proximity sensor appears to be nothing special: a thin, elastic layer of silicone onto which black square surfaces are printed, but these...

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA mission surfs through waves in space to understand space weather

25.07.2017 | Physics and Astronomy

Strength of tectonic plates may explain shape of the Tibetan Plateau, study finds

25.07.2017 | Earth Sciences

The dense vessel network regulates formation of thrombocytes in the bone marrow

25.07.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>